AVCTF (Avacta Group) Cyclically Adjusted PS Ratio: (As of Jul. 05, 2026)


AVCTF Avacta Group PLC AVCTF
13 GF Score
Price $1.00
GF Value $0.67
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Avacta Group Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Avacta Group  (OTCPK:AVCTF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Avacta Group Cyclically Adjusted PS Ratio Related Terms


Avacta Group Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Avacta Group's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avacta Group Cyclically Adjusted PS Ratio Chart

Avacta Group Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.58 20.20 26.93 0.00 0.00

Avacta Group Semi-Annual Data
Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.93 0.00 0.00 0.00 0.00

AVCTF vs VRTX, REGN, ALNY: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Avacta Group's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avacta Group Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avacta Group's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Avacta Group's Cyclically Adjusted PS Ratio falls into.


AVCTF
13GF Score
Avacta Group PLC AVCTF
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avacta Group Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Avacta Group's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Avacta Group's adjusted Revenue per Share data for the fiscal year that ended in Dec25 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=0/139.9000*139.9000
=0.000

Current CPI (Dec25) = 139.9000.

Avacta Group Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201507 0.057 100.000 0.080
201607 0.042 100.900 0.058
201707 0.055 103.500 0.074
201807 0.056 105.900 0.074
202012 0.013 109.400 0.017
202112 0.016 114.700 0.020
202212 0.046 125.300 0.051
202312 0.013 130.500 0.014
202412 0.000 135.100 0.000
202512 0.000 139.900 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Avacta Group (AVCTF) Overvalued in 2026?

Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued. The current stock price of $1.00 is trading 49.3% above its estimated GF Value™ of $0.67. GuruFocus considers Avacta Group to be Significantly Overvalued.

Key valuation signals for AVCTF:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $0.67 vs. price of $1.00 (49.3% above fair value)
  • GF Score™: 13/100 with 8 warning signs

No single metric tells the full story. See the AVCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Avacta Group Business Description

Other Exchanges AVCT:UKRTQ1:Germany
Address 58 Wood Lane, White City Imperial College Campus, Scale Space, London, GBR, W12 7RZ
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
13GF Score

Get the complete analysis for AVCTF

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.00
Price
$0.67
GF Value